Date Mailed: December 4, 2008 Sheet 1 of 1

	FORM 1449*	INEO
1		INFO
2	E //	
	- 6	
1	/	
	~ & \	
1	· · · · · ·	

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 8279.829USWO

Application Number:

10/526858

Applicant: HIDAKA et al.

Filing Date: March 2, 2005

Group Art Unit: 1618

DEMINISTRAÇÃO!		ι	J.S. PATENT DOCUM	ENTS				
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO		
		FOR	REIGN PATENT DOC	UMENTS				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION	
						YES	NO	
	OTHE	D DOCUMENT	0 (I 1 1' A d		I D Till			
		·····	S (Including Author, Tit	· · · · · · · · · · · · · · · · · · · 				
/S.G./			of cDNAs Encoding Cell Molecular Pharmacolog					
/S.G./		KATOH et al. "HMN-214, a Novel Anti-tumor Sulfonamide Compound". Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 38, No. 473, p. 473, (12 April 1997), XP-001061737.						
/S.G./	Compound	KATOH et al. "Mode and Mechanisms of Cell Death Induced by HMN-214, a Novel Anti-tumor Sulfonamide Compound". Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 39, p. 225 (28 March 1998), XP-001061702.						
/S.G./	formation a	MEDINA-GUNDRUM et al. "HMN-176 exhibits marked anticancer activity in ex-vivo human tumor colony formation assay. Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 43, pp. 79-80 (1 March 2002), XP-001538626.						
/S.G./	CALABRE 1225-1232	SI et al. "Chemo (1 Jan. 1996), XI	otherapy of Neoplastic D 2-002973969.	iseases". Pharm	acological Basis of T	Therapeutics, Sec	ction 10, p	

52835 Customer Number

EXAMINER	/Shirley Gembeh/	DATE CONSIDERED	04/09/2009
			5 17 G G / ELO G G

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.